Unknown

Dataset Information

0

Synthesis, Antiviral Bioactivity of Novel 4-Thioquinazoline Derivatives Containing Chalcone Moiety.


ABSTRACT: A series of novel 4-thioquinazoline derivatives containing chalcone moiety were designed, synthesized and systematically evaluated for their antiviral activity against TMV. The bioassay results showed that most of these compounds exhibited moderate to good anti-TMV activity. In particular, compounds M2 and M6 possessed appreciable protection activities against TMV in vivo, with 50% effective concentration (EC50) values of 138.1 and 154.8 ?g/mL, respectively, which were superior to that of Ribavirin (436.0 ?g/mL). The results indicated that chalcone derivatives containing 4-thioquinazoline moiety could effectively control TMV. Meanwhile, the structure-activity relationship (SAR) of the target compounds, studied using the three-dimensional quantitative structure-activity relationship (3D-QSAR) method of comparative molecular field analysis (CoMFA) based on the protection activities against TMV, demonstrated that the CoMFA model exhibited good predictive ability with the cross-validated q2 and non-cross-validated r2 values of 0.674 and 0.993, respectively. Meanwhile, the microscale thermophoresis (MST) experimental showed that the compound M6 may interaction with the tobacco mosaic virus coat protein (TMV CP).

SUBMITTER: Wan Z 

PROVIDER: S-EPMC6332188 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synthesis, Antiviral Bioactivity of Novel 4-Thioquinazoline Derivatives Containing Chalcone Moiety.

Wan Zhihua Z   Hu Deyu D   Li Pei P   Xie Dandan D   Gan Xiuhai X  

Molecules (Basel, Switzerland) 20150629 7


A series of novel 4-thioquinazoline derivatives containing chalcone moiety were designed, synthesized and systematically evaluated for their antiviral activity against TMV. The bioassay results showed that most of these compounds exhibited moderate to good anti-TMV activity. In particular, compounds M2 and M6 possessed appreciable protection activities against TMV in vivo, with 50% effective concentration (EC50) values of 138.1 and 154.8 μg/mL, respectively, which were superior to that of Ribavi  ...[more]

Similar Datasets

| S-EPMC6832660 | biostudies-literature
| S-EPMC8156870 | biostudies-literature
| S-EPMC6100116 | biostudies-literature
| S-EPMC8348251 | biostudies-literature
| S-EPMC9257181 | biostudies-literature
| S-EPMC7424737 | biostudies-literature
| S-EPMC6154619 | biostudies-literature
| S-EPMC10778824 | biostudies-literature
| S-EPMC8600648 | biostudies-literature
| S-EPMC3539435 | biostudies-literature